Cosibelimab is under clinical development by Checkpoint Therapeutics and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Cosibelimab’s likelihood of approval (LoA) and phase transition for Refractory Chronic Lymphocytic Leukemia (CLL) took place on 25 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cosibelimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Cosibelimab is under development for the treatment of hematological malignancies and solid tumor including relapsed and refractory classical Hodgkin lymphoma, relapsed-refractory chronic lymphocytic leukemia (CLL) or Richter's transformation (RT), metastatic non-small cell lung cancer, metastatic non-squamous non-small cell lung cancer, endometrial cancer, colorectal cancer, small-cell lung cancer, malignant pleural mesothelioma, head and neck squamous cell carcinoma, advanced cutaneous squamous cell carcinoma, metastatic melanoma, metastatic Merkel cell carcinoma, renal cell carcinoma and metastatic transitional carcinoma of the urothelium. It is administered by intravenous route. The drug candidate is a fully humanized antibody which acts by targeting PD-L1.
It was also under development for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma
Checkpoint Therapeutics overview
Checkpoint Therapeutics, a subsidiary of Fortress Biotech Inc, is a clinical-stage biopharmaceutical company that acquires, develops, and commercializes novel treatments for solid tumor cancers. Its lead product candidate, CK-101 molecule is in Phase I clinical trials for the treatment of patients with positive epidermal growth factor receptor (EGFR). The company’s other lead product candidate CK-301, is an anti-PD L1 antibody intended for the treatment of patients with non-small cell lung cancer (NSCLC) and other solid tumors. Its other pipeline products include a portfolio of human immuno-oncology agents and targeted anti-cancer agents intended for the treatment of multiple types of cancer including renal cell carcinoma, EGFR mutation-positive NSCLC and multiple forms of cancer. The company also works in partnership with other pharmaceutical companies to co-develop its antibodies. Checkpoint Therapeutics is headquartered in New York, the US.
Quick View Cosibelimab LOA Data
|Highest Development Stage|